NEW YORK, NY / ACCESSWIRE / October 23, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fresenius Medical Care AG & Co. KGaA ("Fresenius" or the "Company") (NYSE:FMS). Investors who purchased Fresenius stock are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/fms.
The investigation concerns whether Fresenius and certain of its officers and/or directors have violated federal securities laws.
On October 21, 2019, Frankfurt prosecutors confirmed German media reports that Fresenius is under investigation for paying millions of dollars in bribes to doctors and state employees in 17 countries in order to persuade foreign clinics to establish dialysis wards and purchase Fresenius dialysis products. On this news, Fresenius's American depositary receipt price fell $2.03 per share, or 5.93%, to close at $32.21 per share on October 22, 2019.
If you are aware of any facts relating to this investigation, or purchased Fresenius shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/fms. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
SOURCE: Bronstein, Gewirtz & Grossman, LLC